Format

Send to

Choose Destination
See comment in PubMed Commons below
Cell Res. 2013 Aug;23(8):975-7. doi: 10.1038/cr.2013.73. Epub 2013 Jun 4.

Differentiation therapy for IDH1/2 mutant malignancies.

Author information

1
Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medical College, 1300 York Ave, New York, NY 10065, USA.

Abstract

Recently discovered recurrent somatic mutations in the key metabolic enzymes IDH1 and IDH2 produce the aberrant oncometabolite 2-HG and contribute to malignant transformation of hematopoietic and glial cells. Two recent reports in Science describe the first IDH1 and IDH2 mutant-specific small-molecule inhibitors, which induce cell differentiation of myeloid leukemias and malignant gliomas.

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center